Abstracts Archive - Page 1817 of 2607 - ACR Meeting Abstracts

Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Fabian Speth¹, Johannes Peter Haas¹ and Claas Hinze², ¹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…
Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Mikhail Kostik¹, Ekaterina Gaidar¹, Margarita Dubko¹, Ludmila Snegireva², Vera Masalova², Irina Chikova¹, Eugenia Isupova³, Tatiana Nikitina⁴, Elena Serogodskaya¹, Olga Kalashnikova¹, Angelo Ravelli⁵ and Vyacheslav Chasnyk³, ¹State Pediatric Medical University, Saint-Petersburg, Russia, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ⁴State Pediatric Medical University, St. Petersburg, Russia, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…
Abstract Number: 2433 • 2015 ACR/ARHP Annual Meeting
Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Claudia Bracaglia¹, Giusi Prencipe¹, Antonio Gatto², Manuela Pardeo¹, Geneviève Lapeyre³, Luigi Raganelli¹, Emiliano Marasco², Antonella Insalaco², Walter Ferlin³, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland
Background/Purpose: Animal and humans data suggest that IFNγ plays a pathogenic role in HLH. A pilot trial in primary HLH with NI-0501, an anti-IFNγ monoclonal…
Abstract Number: 2434 • 2015 ACR/ARHP Annual Meeting
Promis Tools for Measurement of Patient-Reported Outcomes in Children with Juvenile Arthritis
Timothy Brandon¹, Brandon Becker¹, Katherine Bevans¹ and Pamela F. Weiss², ¹Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child/parent perspectives on their own/their child's health are highly pertinent to disease management. PROMIS is a collection of patient-reported outcome measures that were developed…
Abstract Number: 2435 • 2015 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Katerina Jarosova¹, Katerina Andelova², Karel Hejduk³, Michal Uher³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²clinical, Institute for the Care for Mother and Child, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: Biologic drugs are effective therapeutic option in patients with juvenile idiopathic arthritis (JIA). However, data regarding the use during pregnancy and breastfeeding in adult…
Abstract Number: 2436 • 2015 ACR/ARHP Annual Meeting
Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Matthew Basiaga¹, Alexis Ogdie-Beatty² and for the CARRA Investigators, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pneumocystis pneumonia (PCP) is a potentially devastating opportunistic infection. The incidence of PCP and the risk of adverse events secondary to prophylactic medication in…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 2438 • 2015 ACR/ARHP Annual Meeting
Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative
Bernd Koos¹, Peter Stoustrup², Lynn R. Spiegel³, Nikolay Tzaribachev⁴, Troels Herlin⁵, Thomas Klit Pedersen⁶ and Marinka Twilt⁷, ¹Orthodontics, University of Rostock, Rostock, Germany, ²Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, ³Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany, ⁵Department of Pediatrics, Århus University Hospital Skejby, Århus, Denmark, ⁶orthodontics, Aarhus University Hospital/Dental school, Aarhus, Denmark, ⁷Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Arthritis of the temporomandibular joint (TMJ) in patients with Juvenile Idiopathic Arthritis (JIA) is increasingly recognized. In the last decade, studies report that the…
Abstract Number: 2439 • 2015 ACR/ARHP Annual Meeting
Methotrexate Failure in Pediatric Uveitis
Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Daneka Stryker⁴, Steven Tommasello⁵, Curtis Travers¹, Scott R. Lambert², Carolyn Drews-Botsch⁶ and Sheila T. Angeles-Han^1,2,3, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵University of Alabama, Birmingham, AL, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose: Pediatric uveitis can lead to ocular complications and vision loss. Treatment consists of steroid drops, methotrexate (MTX), and anti-tumor necrosis factor (TNF) drugs. Only…
Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting
Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Roberta Berard³, Natalie Shiff⁴, Roman Jurencak⁵, Susanne Benseler⁶, Lori B. Tucker⁷ and ReACCh-Out Investigators, ¹Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Children's Hospital of Western Ontario, London, ON, Canada, ⁴Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…
Abstract Number: 2441 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis
Alan M. Rosenberg¹, Walter Maksymowych², Yuan Gui³ and Anthony Marotta³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., Vancouver, BC, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis…
Abstract Number: 2442 • 2015 ACR/ARHP Annual Meeting
The Family Journey to Diagnosis with Systemic Juvenile Idiopathic Arthritis As Evidenced through Changing Social Media Presence
Renee F Modica¹, Kathleen G Lomax², Pamela Batzel³, Leah Shapardanis³, Kimberly A Compton³ and Melissa E Elder⁴, ¹UF Health Shands Children’s Hospital, Gainesville, FL, ²Medical Affairs, Immunology and Dermatology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³TREATO, Princeton, NJ, ⁴Pediatrics, Univ of Florida, Gainesville, FL
Background/Purpose: Patients with systemic juvenile idiopathic arthritis (SJIA) frequently encounter delays from symptom onset to SJIA diagnosis (dx), partly due to the broad differential of…
Abstract Number: 2443 • 2015 ACR/ARHP Annual Meeting
Pediatric Tele-Rheumatology: A Pilot Project to Assess Accuracy of Physical Examination Findings and Diagnostic Concordance at a Distance
Michael Henrickson¹, Jody Raugh², Kelsey Hofacer³ and Adam Furnier⁴, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Occupational and Physical Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Telehealth, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Quality Improvement Systems, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Telemedicine (TM) offers a strategic means of extending limited clinical pediatric rheumatology (PR) workforce capacity to improve access to care for patients in remote…
Abstract Number: 2444 • 2015 ACR/ARHP Annual Meeting
Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis
Mette Noergaard¹, Johanne Lomholt², Mikael Thastum², Morten Herlin³, Marinka Twilt⁴ and Troels Herlin⁴, ¹Department of Physiotherapy, Aarhus University Hospital, Aarhus, Denmark, ²Psychology and Social Sciences, Aarhus University, Aarhus, Denmark, ³Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) has been associated with decreased physical activity (PA). However, accurate, objective measurements of PA related to potential factors limiting PA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].